S233 CAR T cells

S233 CAR T cells are an experimental fourth-generation "armored" chimeric antigen receptor (CAR) T-cell therapy developed by researchers at the Geisel School of Medicine at Dartmouth. These cells are genetically engineered to constitutively secrete two potent immunomodulatory cytokines: Super2 and Interleukin-33 (IL-33). Super2 is a modified IL-2 super-agonist designed with enhanced affinity for the IL-2 receptor beta subunit (CD122) to promote T-cell expansion while minimizing the activation of regulatory T cells. IL-33 is a member of the IL-1 family that enhances the effector function and persistence of T cells. This dual-cytokine armoring strategy is intended to overcome the immunosuppressive tumor microenvironment of solid tumors by improving CAR T-cell infiltration, persistence, and the recruitment of endogenous immune cells. Preclinical studies in melanoma models have shown that S233 CAR T cells can induce the formation of tissue-resident memory (TRM) cells and provide durable anti-tumor protection, particularly when combined with checkpoint inhibitors or CD4+ T-cell depletion.

Other names

Super2 and IL-33 armored CAR T cellsSuper-2 and IL-33 armored CAR T cellsSuper 2 and IL-33 armored CAR T cellsSuper2/IL-33 armored CAR T cells